I Solovic, M Sester, J J Gomez-Reino, H L Rieder, S Ehlers, H J Milburn, B Kampmann, B Hellmich, R Groves, S Schreiber, R S Wallis, G Sotgiu, E H Schölvinck, D Goletti, J P Zellweger, R Diel, L Carmona, F Bartalesi, P Ravn, A Bossink, R Duarte, C Erkens, J Clark, G B Migliori, C Lange
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used...
November 2010: European Respiratory Journal